在充满挑战的市场环境中，Alector Inc. (ALEC)股价触及52周新低，跌至2.61美元。这一显著下跌反映了该生物技术公司的整体趋势，过去一年其股价下跌了20.16%。投资者正密切关注Alector的表现，因为该公司正在经历一个充满波动和投资者谨慎的时期，希望公司的战略举措最终能够引导其重回增长和复苏的轨道。

Alector’s AbbVie-partnered Alzheimer's disease asset has failed to slow disease progression in a phase 2 study, the latest in ...

Alector has significant cash reserves but faces high cash burn, with no immediate catalysts and uncertain prospects for its ...

Alector is kicking off a resource realignment effort that will include a workforce reduction of around 17%. The biotech ...

南旧金山 - 专注于神经退行性疾病的生物科技公司Alector, Inc.

【11 月 26 日，美国生物制药公司 Alector(ALEC.US)盘前跌超 33.5%，报 2.63 美元。】消息显示，Alector 公司的实验性药物在一项中期试验中未达减缓阿尔茨海默氏症进展的主要终点，将停止该药物的长期扩展研究。此外，该公司计划在 2023 年 12 月 31 日前裁员 17%，涉及 244 ...

Cantor Fitzgerald reiterated their overweight rating on shares of Alector (NASDAQ:ALEC – Free Report) in a research report ...

Alector, Inc. (NASDAQ:ALEC – Free Report) – HC Wainwright issued their Q1 2025 EPS estimates for shares of Alector in a ...

H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on Alector (ALEC) to $7 from $35 and keeps a Buy rating ...

Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's ...

11月26日｜美国生物制药公司Alector (ALEC.US) ...

The brain drug developer is letting go of around 41 of its 238 employees, in a move the company says will help “align ...